BioXcel Therapeutics, Inc.
USPTO PatentsView assignee record - 17 granted patents across 2 technology areas, recorded in grant years 2020–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).
The verdict
According to USPTO PatentsView, Bioxcel ranks #16,639 of 49,997 tracked US assignees by granted-patent volume, with 17 patents across 2 technology areas.
- #16,639
- of 49,997 US assignees by volume
- Top 25%
- by Innovation Score (44.8/100)
- 16.4
- avg claims per patent
USPTO PatentsView assignee plate
Corpus R16639 · US Corporation #16,639 · 17 grants
GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-PAR · CLAIMS-RICH · TYPE-USCORP · SPAN-YRS · BOOK-RICH
- GRANTS-MICRO 17 grants
- MID-PACK #16,639/49,997
- PHOTO-FINISH Beijing Rockrobo…
- CPC-NARROW A61P · 2 areas
- INNOV-PAR 44.8/100
- CLAIMS-RICH 16.4 claims/avg
- TYPE-USCORP US Corporation
- SPAN-YRS 2020–2025 · 6y
- BOOK-RICH 9/10 fields
Nearest grant-volume peer: Beijing Rockrobo Technology Co., Ltd. (±0 grants)
Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.
How Bioxcel’s 44.8 Innovation Score adds up
The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.
Innovation-score neighbourhood around Bioxcel
Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.
- Qualcomm Incorporated · highest
Qualcomm Incorporated · highest
85 score
- BioXcel Therapeutics · this assignee
BioXcel Therapeutics · this assignee
45 score
- 3D Lighting… · lowest 7
3D Lighting… · lowest
7 score
What this shows Bioxcel's Innovation Score is 44.8/100 (top 25% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.
Does more volume mean deeper claims for Bioxcel?
Each dot is one of Bioxcel’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Bioxcel’s own 16.4 claims/patent is ABOVE the 12.0 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.
Where Bioxcel's grants concentrate
BioXcel Therapeutics, Inc. is a focused PatentsView assignee: 2 CPC subclasses with 100% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2024 (7 grants) versus a trough of 1 in 2020. By volume, Bioxcel sits between Beijing Rockrobo Technology Co., Ltd. and Blackbird Technology Holdings, Inc..
Bioxcel's three-year grant acceleration
BioXcel Therapeutics, Inc. shows 15 grants in 2022–2024 against only 1 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.
Who files at BioXcel's volume?
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
- Beijing Rockrobo…
Beijing Rockrobo Technology Co., Ltd.
17 patents
- Benshot
BenShot, LLC
17 patents
- Beyondspring Pham…
BeyondSpring Phamaceuticals, Inc.
17 patents
- Biolinerx
BioLineRx Ltd.
17 patents
- Bioaxial SAS
Bioaxial SAS
17 patents
- Biological Innova…
Biological Innovation and Optimization Systems, LLC
17 patents
- Biora Therapeutics
Biora Therapeutics, Inc.
17 patents
- Blackbird Technol…
Blackbird Technology Holdings, Inc.
17 patents
- Bioxcel Therapeut… ◀
BioXcel Therapeutics, Inc.
17 patents
What this shows BioXcel holds 17 patents at rank #16,648, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
Companies ranked near BioXcel
By rank, the assignees closest to #16,648 in granted patent volume.
- Beijing Rockrobo Technology Co., Ltd. #16,644 · 17 patents
- BenShot, LLC #16,645 · 17 patents
- BeyondSpring Phamaceuticals, Inc. #16,646 · 17 patents
- BioLineRx Ltd. #16,647 · 17 patents
- Bioaxial SAS #16,649 · 17 patents
- Biological Innovation and Optimization Systems, LLC #16,650 · 17 patents
- Biora Therapeutics, Inc. #16,651 · 17 patents
- Blackbird Technology Holdings, Inc. #16,652 · 17 patents
Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)
Other assignees with the most granted patents in BioXcel's primary technology class.
- The Regents of the University of California 1,387 in class
- Novartis AG 1,071 in class
- Merck Sharp & Dohme LLC 889 in class
- Bristol-Myers Squibb Company 879 in class
- Genentech, Inc. 789 in class
- The Board of Regents of the University of Texas System 744 in class
- Hoffmann-La Roche Inc. 722 in class
- The United States of America, as represented by the Secretary, Department of Health and Human Services 721 in class
Bioxcel's Innovation Score vs. every tracked assignee
Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)
45 Top 25% higher than 75% of 49,997 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Grants by year
Teal-shaded recent years (2020–present) versus the 2020–2019 baseline. Full figures in the table below.
View data table
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2020 | 1 | 5.9% |
| 2022 | 3 | 17.6% |
| 2023 | 5 | 29.4% |
| 2024 | 7 | 41.2% |
| 2025partial year | 1 | 5.9% |
Which technologies does BioXcel Therapeutics, Inc. patent most?
Top 2 of 2 technology areas
Data Source
USPTO PatentsView, US granted patents 2015–2025
What to do with this data
BioXcel Therapeutics, Inc.'s patent record in context - here's where to go next.
- BioXcel Therapeutics, Inc.'s lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 100% of its portfolio - see every assignee active in that class. Explore A61P
- Ranked #16,639 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
- Compare BioXcel Therapeutics, Inc. against Beijing Rockrobo Technology Co., Ltd., an assignee filing at a similar volume. Compare portfolios
- Innovation Score of 44.8/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated
Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.